Intercept Pharmaceuticals, Inc.

( )
ICPT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.19%163.530.7%$1333.35m
LLYEli Lilly & Co. 0.74%323.991.1%$1075.80m
ABBVAbbVie, Inc. 0.94%139.601.9%$860.15m
PFEPfizer Inc. 0.48%44.320.9%$801.41m
BMYBristol-Myers Squibb Co. -0.01%70.531.0%$772.67m
MRKMerck & Co., Inc. 0.46%87.960.7%$713.70m
AZNAstraZeneca Plc 1.58%56.431.0%$393.63m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%196.798.2%$217.39m
GSKGSK Plc 1.75%30.760.3%$213.18m
NVSNovartis AG 1.67%77.950.2%$205.02m
ATXIAvenue Therapeutics, Inc. 41.70%16.310.0%$197.40m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.485.4%$191.16m
IDXXIDEXX Laboratories, Inc. 1.10%340.393.9%$186.31m
HZNPHorizon Therapeutics Plc 0.00%64.265.4%$173.65m
SRPTSarepta Therapeutics, Inc. 0.00%109.9412.4%$136.73m

Company Profile

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.